Copay Accumulator Programs & Pharma: What’s Next?

A closer look at CAPs and how they might affect your brand

Dynamics between pharma and the market-based healthcare sector it serves have invariably been complex, with one of the biggest drivers of that complexity being effective management of patient demand and payer systems.

And over time, payer business models are becoming increasingly convoluted. The newest stratagem in this push and pull is the copay accumulator program, or CAP. First introduced in 2018, these programs are now rapidly being rolled out by payers, with data showing that nearly one-third of commercially insured patients are now directly impacted by CAPs – enrolled either in plans that have implemented copay accumulator adjustment or closely-related copay maximizers.

The CAP, with its differing and confusing scopes of application, is one more contour to successfully navigate when attempting to balance clinical and economic value in product development and commercialization decisions.

What is a CAP?

Copay accumulator programs (CAPs) permit employers and PBMs to exclude copay assistance from the calculation of a patient’s annual deductible, effectively negating the value of the copay assistance for said patient.

Prior to the introduction of the CAP, payers sought to guide patients toward less expensive treatments by making them pay a higher portion of a drug’s costs. Drug-makers responded by increasing the financial aid they offer, in the form of copay assistance, to shield consumers from these rising expenses. Payers, however, have now turned the tables on Pharma. They are using CAPs to leverage the value of the manufacturer copay coupon, in turn increasing beneficiary cost-sharing amounts to meet deductible amounts.

Deallus Copay Accumulator Programs Pharma White Paper
DOWNLOAD WHITE PAPER

You may also be interested in…

  • HIV & AIDS Medication

HIV/AIDS

Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).

  • Post-ASCO 2022- Summary of key breast cancer highlights

Post-ASCO 2022: Summary of key breast cancer highlights

With the conclusion of another ASCO, we were presented with exciting new breakthrough data of Antibody Drug Conjugates in breast cancer. Enhertu (trastuzumab deruxtecan) demonstrated significant benefit in the treatment of a new subtype of breast cancer, HR+/ /HER2-low.

BIO 2022: Biotechnology Innovation Organization (BIO) Convention

We’re excited to be attending The BIO International Convention. Jack Florio, Partner in Strategy Consulting at Deallus will be joining more than 3,000 delegates and exploring the latest innovation within the biotech space, as well as making the most of opportunities to meet and network with global thought leaders and industry peers.

To learn more about this topic, or to find out about ways in which Deallus can help you, please get in touch.

For any questions or comments on this thought piece, please reach out to Julie Munch Khan – Deallus Chief Commercial Officer

Julie Munch Khan – Deallus Chief Commercial Officer